Wyeth Presents New Phase 3 Data And Updates Regulatory Timing For NDA Filing Of Bazedoxifene/Conjugated Estrogens
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), presented new data from two Phase 3 studies, which showed that bazedoxifene/conjugated estrogens reduced the number and severity of hot flashes in symptomatic postmenopausal women by up to 80 percent, when compared with placebo. These data, presented at the North American Menopause Society Annual Meeting, also showed that bazedoxifene/conjugated estrogens improved symptoms of vulvar and vaginal atrophy.
